A. Boutan-Laroze , M. Mahjoubi , J.P. Droz , P. Charrot , P. Fargeot , P. Kerbrat , A. Caty , P.M. Voisin , M. Spielmann , A. Rey , B. Giraud
{"title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder","authors":"A. Boutan-Laroze , M. Mahjoubi , J.P. Droz , P. Charrot , P. Fargeot , P. Kerbrat , A. Caty , P.M. Voisin , M. Spielmann , A. Rey , B. Giraud","doi":"10.1016/0277-5379(91)90447-L","DOIUrl":null,"url":null,"abstract":"<div><p>70 patients with advanced transitional cell carcinoma of the bladder received methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). Complete responses (CR) were obtained in 13 of the 67 (19%) evaluable patients and partial responses (PR) in 25 patients for an objective response rate of 57% (95% CI 45–69%). Of the 54 patients who have had a minimum follow-up of 2 years, 8 patients (15%) are disease-free or have stable residual disease. Median survival of the 70 patients was 13 months. Toxicity was acceptable with no drug-related deaths. Because of myelosuppression, only 15 patients (21%) received treatment without delays in drug administration or modifications from the planned schedule. Our results confirm that this regimen is effective, with some patients being long-term survivors.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90447-L","citationCount":"63","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190447L","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 63
Abstract
70 patients with advanced transitional cell carcinoma of the bladder received methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). Complete responses (CR) were obtained in 13 of the 67 (19%) evaluable patients and partial responses (PR) in 25 patients for an objective response rate of 57% (95% CI 45–69%). Of the 54 patients who have had a minimum follow-up of 2 years, 8 patients (15%) are disease-free or have stable residual disease. Median survival of the 70 patients was 13 months. Toxicity was acceptable with no drug-related deaths. Because of myelosuppression, only 15 patients (21%) received treatment without delays in drug administration or modifications from the planned schedule. Our results confirm that this regimen is effective, with some patients being long-term survivors.
70例晚期膀胱移行细胞癌患者接受甲氨蝶呤、长春花碱、阿霉素和顺铂(M-VAC)治疗。67例可评估患者中有13例(19%)获得完全缓解(CR)， 25例患者获得部分缓解(PR)，客观缓解率为57% (95% CI 45-69%)。在54例至少随访2年的患者中，8例患者(15%)无病或有稳定的残余疾病。70例患者的中位生存期为13个月。毒性是可接受的，没有与药物相关的死亡。由于骨髓抑制，只有15名患者(21%)接受了治疗，没有延迟给药或改变计划的时间表。我们的研究结果证实，这种治疗方案是有效的，一些患者长期存活。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
